Acinetobacter Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Acinetobacter Infections Drugs Development Market Overview
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections – Drugs In Development, 2022, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.
Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 8, 45, 21 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 7 molecules, respectively.
Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Adaptive Phage Therapeutics Inc
AGILeBiotics BV
Alterity Therapeutics Ltd
Antabio SAS
Appili Therapeutics Inc
Arch Biopartners Inc
Aridis Pharmaceuticals Inc
Armata Pharmaceuticals Inc
Asieris Pharmaceuticals Co Ltd
AstraZeneca Plc
Atterx Biotherapeutics Inc
Aurora Oncology Inc
Bioharmony Therapeutics Inc
Biological Anti-Infective Medicines LLC
Biomendics LLC
Bioversys AG
Bugworks Research India Pvt Ltd
Celdara Medical LLC
Centauri Therapeutics Ltd
Clarametyx Biosciences Inc
ContraFect Corp
Danuvius BioSciences
Debiopharm International SA
Entasis Therapeutics Holdings Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Hsiri Therapeutics LLC
Idorsia Pharmaceutical Ltd
Infextious Therapeutic
Inhibrx Inc
KBP Biosciences Co Ltd
Linnaeus Bioscience Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
MetalloBio Ltd
Mutabilis SA
Nektr Technologies Ltd
Neoculi Pty Ltd
Novabiotics Ltd
Omnix Medical Ltd
Oxford Drug Design Ltd
Pedanius Therapeutics Ltd
Peptilogics Inc
Pylum Biosciences Inc
Qpex Biopharma Inc
Recce Pharmaceuticals Ltd
Redx Pharma Plc
RMH Sciences LLC
Shanghai Space Peptides Pharmaceutical Co Ltd
Shionogi & Co Ltd
Spero Therapeutics Inc
Spexis AG
Summit Therapeutics Inc
Techulon Inc
Vaxdyn SL
VenatoRx Pharmaceuticals Inc
Venus Medicine Research Centre
Vitas Pharma Research Pvt Ltd
Xellia Pharmaceuticals ApS
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Infectious Disease reports